Literature DB >> 17724476

Regulation of cyclin D1 expression by mTORC1 signaling requires eukaryotic initiation factor 4E-binding protein 1.

J Averous1, B D Fonseca, C G Proud.   

Abstract

There is currently substantial interest in the regulation of cell function by mammalian target of rapamycin (mTOR), especially effects linked to the rapamycin-sensitive mTOR complex 1 (mTORC1). Rapamycin induces G(1) arrest and blocks proliferation of many tumor cells, suggesting that the inhibition of mTORC1 signaling may be useful in cancer therapy. In MCF7 breast adenocarcinoma cells, rapamycin decreases levels of cyclin D1, without affecting cytoplasmic levels of its mRNA. In some cell-types, rapamycin does not affect cyclin D1 levels, whereas the starvation for leucine (which impairs mTORC1 signaling more profoundly than rapamycin) does. This pattern correlates with the behavior of eukaryotic initiation factor 4E-binding protein 1 (4E-BP1, an mTORC1 target that regulates translation initiation). siRNA-mediated knock-down of 4E-BP1 abrogates the effect of rapamycin on cyclin D1 expression and increases the polysomal association of the cyclin D1 mRNA. Our data identify 4E-BP1 as a key regulator of cyclin D1 expression, indicate that this effect is not mediated through the changes in cytoplasmic levels of cyclin D1 mRNA and suggest that, in some cell types, interfering with the amino acid input to mTORC1, rather than using rapamycin, may inhibit proliferation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17724476     DOI: 10.1038/sj.onc.1210715

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  70 in total

1.  S6 kinase 1 is required for rapamycin-sensitive liver proliferation after mouse hepatectomy.

Authors:  Catherine Espeillac; Claudia Mitchell; Séverine Celton-Morizur; Céline Chauvin; Vonda Koka; Cynthia Gillet; Jeffrey H Albrecht; Chantal Desdouets; Mario Pende
Journal:  J Clin Invest       Date:  2011-07       Impact factor: 14.808

2.  ATG4B promotes colorectal cancer growth independent of autophagic flux.

Authors:  Pei-Feng Liu; Chung-Man Leung; Yu-Hsiang Chang; Jin-Shiung Cheng; Jih-Jung Chen; Chung-Jeu Weng; Kuo-Wang Tsai; Chien-Jen Hsu; Yen-Chen Liu; Ping-Chi Hsu; Hung-Wei Pan; Chih-Wen Shu
Journal:  Autophagy       Date:  2014-06-12       Impact factor: 16.016

3.  cAMP-dependent activation of mammalian target of rapamycin (mTOR) in thyroid cells. Implication in mitogenesis and activation of CDK4.

Authors:  Sara Blancquaert; Lifu Wang; Sabine Paternot; Katia Coulonval; Jacques E Dumont; Thurl E Harris; Pierre P Roger
Journal:  Mol Endocrinol       Date:  2010-05-19

4.  The anti-ovarian cancer activity by WYE-132, a mTORC1/2 dual inhibitor.

Authors:  Dan Zhang; Hexia Xia; Wei Zhang; Bo Fang
Journal:  Tumour Biol       Date:  2015-08-21

5.  Rottlerin induces Wnt co-receptor LRP6 degradation and suppresses both Wnt/β-catenin and mTORC1 signaling in prostate and breast cancer cells.

Authors:  Wenyan Lu; Cuihong Lin; Yonghe Li
Journal:  Cell Signal       Date:  2014-03-06       Impact factor: 4.315

6.  Rheb1-Independent Activation of mTORC1 in Mammary Tumors Occurs through Activating Mutations in mTOR.

Authors:  Bin Xiao; Dongmei Zuo; Alison Hirukawa; Robert D Cardiff; Richard Lamb; Nahum Sonenberg; William J Muller
Journal:  Cell Rep       Date:  2020-04-28       Impact factor: 9.423

7.  A reduction in Pten tumor suppressor activity promotes ErbB-2-induced mouse prostate adenocarcinoma formation through the activation of signaling cascades downstream of PDK1.

Authors:  Olga C Rodriguez; Edwin W Lai; Sarada Vissapragada; Caroline Cromelin; Maral Avetian; Patricia Salinas; Hida Ramos; Bhaskar Kallakury; Mathew Casimiro; Michael P Lisanti; Herbert B Tanowitz; Karel Pacak; Robert I Glazer; Maria Avantaggiati; Chris Albanese
Journal:  Am J Pathol       Date:  2009-05-14       Impact factor: 4.307

8.  Temsirolimus in the treatment of relapsed or refractory mantle cell lymphoma.

Authors:  Nousheen Samad; Anas Younes
Journal:  Onco Targets Ther       Date:  2010-09-07       Impact factor: 4.147

9.  Translational control of cyclins.

Authors:  Woan-Yuh Tarn; Ming-Chih Lai
Journal:  Cell Div       Date:  2011-02-11       Impact factor: 5.130

10.  NF2/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth.

Authors:  Marianne F James; Sangyeul Han; Carolyn Polizzano; Scott R Plotkin; Brendan D Manning; Anat O Stemmer-Rachamimov; James F Gusella; Vijaya Ramesh
Journal:  Mol Cell Biol       Date:  2009-05-18       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.